Suppr超能文献

MR 引导下的腹腔外韧带样瘤聚焦超声治疗:105 例患者的多中心回顾性研究。

MR-guided focused ultrasound therapy of extra-abdominal desmoid tumors: a multicenter retrospective study of 105 patients.

机构信息

Department of Radiology, Stanford University, Stanford, CA, USA.

UCSF Department of Radiology & Biomedical Imaging, San Francisco, USA.

出版信息

Eur Radiol. 2024 Feb;34(2):1137-1145. doi: 10.1007/s00330-023-10073-9. Epub 2023 Aug 24.

Abstract

OBJECTIVE

To assess the safety and efficacy of magnetic resonance-guided focused ultrasound (MRgFUS) for the treatment extra-abdominal desmoids.

METHODS

A total of 105 patients with desmoid fibromatosis (79 females, 26 males; 35 ± 14 years) were treated with MRgFUS between 2011 and 2021 in three centers. Total and viable tumors were evaluated per patient at last follow-up after treatment. Response and progression-free survival (PFS) were assessed with (modified) response evaluation criteria in solid tumors (RECIST v.1.1 and mRECIST). Change in Numerical Rating Scale (NRS) pain and 36-item Short Form Health Survey (SF-36) scores were compared. Treatment-related adverse events were recorded.

RESULTS

The median initial tumor volume was 114 mL (IQR 314 mL). After MRgFUS, median total and viable tumor volume decreased to 51 mL (95% CI: 30-71 mL, n = 101, p < 0.0001) and 29 mL (95% CI: 17-57 mL, n = 88, p < 0.0001), respectively, at last follow-up (median: 15 months, 95% CI: 11-20 months). Based on total tumor measurements (RECIST), 86% (95% CI: 75-93%) had at least stable disease or better at last follow-up, but 50% (95% CI: 38-62%) of remaining viable nodules (mRECIST) progressed within the tumor. Median PFS was reached at 17 and 13 months for total and viable tumors, respectively. NRS decreased from 6 (IQR 3) to 3 (IQR 4) (p < 0.001). SF-36 scores improved (physical health (41 (IQR 15) to 46 (IQR 12); p = 0.05, and mental health (49 (IQR 17) to 53 (IQR 9); p = 0.02)). Complications occurred in 36%, most commonly 1/2 degree skin burns.

CONCLUSION

MRgFUS reduced tumor volume, reduced pain, and improved quality of life in this series of 105 patients with extra-abdominal desmoid fibromatosis.

CLINICAL RELEVANCE STATEMENT

Imaging-guided ablation is being increasingly used as an alternative to surgery, radiation, and medical therapy for the treatment of desmoid fibromatosis. MR-guided high-intensity focused ultrasound is an incisionless ablation technique that can be used to reduce tumor burden effectively and safely.

KEY POINTS

• Desmoid fibromatosis was treated with MR-guided high-intensity focused ultrasound in 105 patients. • MR-guided focused ultrasound ablation reduced tumor volume and pain and improved quality of life. • MR-guided focused ultrasound is a treatment option for patients with extra-abdominal desmoid tumors.

摘要

目的

评估磁共振引导聚焦超声(MRgFUS)治疗腹外部位纤维瘤病的安全性和有效性。

方法

2011 年至 2021 年间,在三个中心,共对 105 例纤维瘤病(79 名女性,26 名男性;35±14 岁)患者进行了 MRgFUS 治疗。治疗后,对每位患者的总肿瘤和有活力肿瘤进行了最后随访评估。采用(改良)实体瘤反应评价标准(RECIST v.1.1 和 mRECIST)评估反应和无进展生存期(PFS)。比较数字评分量表(NRS)疼痛评分和 36 项简明健康调查量表(SF-36)评分的变化。记录与治疗相关的不良事件。

结果

中位初始肿瘤体积为 114ml(IQR 314ml)。经 MRgFUS 治疗后,中位总肿瘤和有活力肿瘤体积分别在最后随访时降低至 51ml(95%CI:30-71ml,n=101,p<0.0001)和 29ml(95%CI:17-57ml,n=88,p<0.0001)。(中位数:15 个月,95%CI:11-20 个月)。基于总肿瘤测量值(RECIST),86%(95%CI:75-93%)在最后随访时至少有稳定疾病或更好的反应,但仍有 50%(95%CI:38-62%)的剩余有活力结节(mRECIST)在肿瘤内进展。总肿瘤和有活力肿瘤的中位 PFS 分别为 17 个月和 13 个月。NRS 从 6(IQR 3)降低至 3(IQR 4)(p<0.001)。SF-36 评分改善(生理健康(41(IQR 15)至 46(IQR 12);p=0.05,心理健康(49(IQR 17)至 53(IQR 9);p=0.02))。并发症发生率为 36%,最常见的是 1/2 度皮肤烧伤。

结论

在这一系列 105 例腹外部位纤维瘤病患者中,MRgFUS 降低了肿瘤体积,减轻了疼痛,并改善了生活质量。

临床相关性声明

成像引导消融术正越来越多地被用作手术、放疗和药物治疗的替代方法,用于治疗纤维瘤病。MR 引导高强度聚焦超声是一种非切口消融技术,可有效、安全地降低肿瘤负荷。

重点

• 105 例纤维瘤病患者接受了磁共振引导高强度聚焦超声治疗。• MR 引导聚焦超声消融术降低了肿瘤体积和疼痛,改善了生活质量。• MR 引导聚焦超声是治疗腹外部位纤维瘤病的一种治疗选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验